COVID-19 outbreak in Italy: an opportunity to evaluate extended interval dosing of ocrelizumab in MS patients.
Bisecco A, Matrone F, Capobianco M, De Luca G, Filippi M, Granella F, Lus G, Marfia GA, Mirabella M, Patti F, Trojano M, Mascolo A, Copetti M, Tedeschi G, Gallo A; OCREVID study group on behalf of the Italian MS Register.
Bisecco A, et al. Among authors: copetti m.
J Neurol. 2024 Feb;271(2):699-710. doi: 10.1007/s00415-023-12084-4. Epub 2023 Nov 20.
J Neurol. 2024.
PMID: 37982852
Free PMC article.